Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 612 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · derivative · entry 9 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 612 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock on 5/4/2024. Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Tax withholdingCommon Stock | 302 | $127.51 | $38,508.02 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · nonDerivative · entry 6 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,428.286 Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionCommon Stock | 612 | $127.51 | $78,036.12 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · nonDerivative · entry 5 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,730.286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · derivative · entry 8 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,532 Underlying: Common Stock · 1,530 shares Expires 2025-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in equal, annual installments with one installment having vested on 5/3/2024 and the last installment to vest on 5/3/2025. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 516 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · derivative · entry 7 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518 Underlying: Common Stock · 516 shares Expires 2025-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in equal, annual installments with one installment having vested on 5/3/2024 and the last installment to vest on 5/3/2025. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Tax withholdingCommon Stock | 590 | $128.26 | $75,673.40 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · nonDerivative · entry 4 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,118.286 Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionCommon Stock | 1,530 | $128.26 | $196,237.80 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · nonDerivative · entry 3 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,708.286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Tax withholdingCommon Stock | 255 | $128.26 | $32,706.30 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · nonDerivative · entry 2 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,178.286 Read SEC document |
| May 03, 2024 Filed May 6, 2024 20:10 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionCommon Stock | 516 | $128.26 | $66,182.16 |
DisclosureSEC source: 0001127602-24-014271 · form4.xml · nonDerivative · entry 1 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433.286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:23 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 381 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013981 · form4.xml · derivative · entry 5 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764 Underlying: Common Stock · 381 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:23 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Tax withholdingCommon Stock | 131 | $128.80 | $16,872.80 |
DisclosureSEC source: 0001127602-24-013981 · form4.xml · nonDerivative · entry 2 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,917.286 F1 · balance_after: Includes .041 shares of Merck & Co., Inc. common stock not previously reported due to a clerical error. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:23 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionCommon Stock | 381 | $128.80 | $49,072.80 |
DisclosureSEC source: 0001127602-24-013981 · form4.xml · nonDerivative · entry 1 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,048.286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:29 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · derivative · entry 5 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,524 Underlying: Common Stock · 2,262 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:29 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Tax withholdingCommon Stock | 1,115 | $128.80 | $143,612.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · nonDerivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,716.325 Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:29 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Exercise / conversionCommon Stock | 2,262 | $128.80 | $291,345.60 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,831.325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:05 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013916 · form4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2034-04-29 F5 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:05 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
GrantRestricted Stock Unit · Derivative | 23,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013916 · form4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,216 Underlying: Common Stock · 23,216 shares Expires 2027-04-30 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest in full and are distributed as shares of Merck & Co., Inc. common stock on 04/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:07 UTC |
Litchfield CarolineEVP & CFO
|
GrantStock Option (Right to Buy) · Derivative | 49,805 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013922 · form4.xml · derivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,805 Underlying: Common Stock · 49,805 shares Expires 2034-04-29 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:09 UTC |
Klobuchar Michael AEVP - Chief Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 20,508 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013930 · form4.xml · derivative · entry 6 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,508 Underlying: Common Stock · 20,508 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:11 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
GrantStock Option (Right to Buy) · Derivative | 16,406 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013937 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,406 Underlying: Common Stock · 16,406 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:13 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantStock Option (Right to Buy) · Derivative | 38,672 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013943 · form4.xml · derivative · entry 5 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,672 Underlying: Common Stock · 38,672 shares Expires 2034-04-29 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:14 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
GrantStock Option (Right to Buy) · Derivative | 181,641 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013947 · form4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,641 Underlying: Common Stock · 181,641 shares Expires 2034-04-29 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:15 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
GrantStock Option (Right to Buy) · Derivative | 20,508 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013953 · form4.xml · derivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,508 Underlying: Common Stock · 20,508 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:17 UTC |
Li Dean YExecutive VP & President, MRL
|
GrantStock Option (Right to Buy) · Derivative | 65,625 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013958 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Stock · 65,625 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:19 UTC |
Zachary JenniferEVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 35,156 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013964 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,156 Underlying: Common Stock · 35,156 shares Expires 2034-04-29 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:20 UTC |
Downing Cristal NChief Comm. & Public Afrs Ofcr
|
GrantStock Option (Right to Buy) · Derivative | 15,234 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013970 · form4.xml · derivative · entry 1 Downing Cristal N · CIK 0001879216 · Chief Comm. & Public Afrs Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,234 Underlying: Common Stock · 15,234 shares Expires 2034-04-29 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:22 UTC |
Guindo ChirfiChief Marketing Officer
|
GrantStock Option (Right to Buy) · Derivative | 29,297 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013976 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,297 Underlying: Common Stock · 29,297 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:23 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
GrantStock Option (Right to Buy) · Derivative | 7,031 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013981 · form4.xml · derivative · entry 4 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,031 Underlying: Common Stock · 7,031 shares Expires 2034-04-29 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:23 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
GrantRestricted Stock Unit · Derivative | 1,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013981 · form4.xml · derivative · entry 3 Smart Dalton · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,393 Underlying: Common Stock · 1,393 shares Expires 2027-04-30 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:25 UTC |
Larson Betty DEVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 31,055 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013989 · form4.xml · derivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,055 Underlying: Common Stock · 31,055 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:25 UTC |
Larson Betty DEVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 58,594 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013989 · form4.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,594 Underlying: Common Stock · 58,594 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:25 UTC |
Larson Betty DEVP, Chief HR Officer
|
GrantRestricted Stock Unit · Derivative | 34,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013989 · form4.xml · derivative · entry 1 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,050 Underlying: Common Stock · 34,050 shares Expires 2027-04-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:29 UTC |
Romanelli JosephPresident, Human Health Int?l
|
GrantStock Option (Right to Buy) · Derivative | 23,438 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · derivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,438 Underlying: Common Stock · 23,438 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:29 UTC |
Romanelli JosephPresident, Human Health Int?l
|
GrantRestricted Stock Unit · Derivative | 6,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · derivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,191 Underlying: Common Stock · 6,191 shares Expires 2027-04-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:12 UTC |
Coe Mary EllenDirector
|
GrantPhantom Stock · Derivative | 227.3588 | $131.95 | $29,999.99 |
DisclosureSEC source: 0001127602-24-011444 · form4.xml · derivative · entry 2 Coe Mary Ellen · CIK 0001691304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,049.6628 Underlying: Common Stock · 227.3588 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:14 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 341.0383 | $131.95 | $45,000.00 |
DisclosureSEC source: 0001127602-24-011446 · form4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,360.3983 Underlying: Common Stock · 341.0383 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:16 UTC |
Seidman Christine EDirector
|
GrantPhantom Stock · Derivative | 61.5764 | $131.95 | $8,125.01 |
DisclosureSEC source: 0001127602-24-011448 · form4.xml · derivative · entry 2 Seidman Christine E · CIK 0001805745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,920.1071 Underlying: Common Stock · 61.5764 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:18 UTC |
Wendell Peter CDirector
|
GrantPhantom Stock · Derivative | 227.3588 | $131.95 | $29,999.99 |
DisclosureSEC source: 0001127602-24-011450 · form4.xml · derivative · entry 2 WENDELL PETER C · CIK 0001032635 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,752.6198 Underlying: Common Stock · 227.3588 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 85,021 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · derivative · entry 9 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,760 Underlying: Common Stock · 85,021 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
SaleCommon Stock | 85,021 | $125.40 | $10,661,573.89 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · nonDerivative · entry 6 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,326.757 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.0900 to $125.8200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
Exercise / conversionCommon Stock | 85,021 | $73.73 | $6,268,598.33 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · nonDerivative · entry 5 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 433,347.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 21:03 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 38,291 | $0.00 Strike: $58.08 | $0.00 |
DisclosureSEC source: 0001127602-24-005196 · form4.xml · derivative · entry 3 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,291 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The option vested and became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 21:03 UTC |
Litchfield CarolineEVP & CFO
|
SaleCommon Stock | 38,291 | $125.50 | $4,805,520.50 |
DisclosureSEC source: 0001127602-24-005196 · form4.xml · nonDerivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,908.194 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.5000 to $125.5050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 21:03 UTC |
Litchfield CarolineEVP & CFO
|
Exercise / conversionCommon Stock | 38,291 | $58.08 | $2,223,941.28 |
DisclosureSEC source: 0001127602-24-005196 · form4.xml · nonDerivative · entry 1 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,199.194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 21:03 UTC |
Romanelli JosephPresident, Human Health Int?l
|
SaleCommon Stock | 1,000 | $124.89 | $124,887.90 |
DisclosureSEC source: 0001127602-24-004993 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,569.325 Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 108,491 | $0.00 Strike: $73.73 | $0.00 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · derivative · entry 8 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,781 Underlying: Common Stock · 108,491 shares Expires 2031-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F6 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 41,509 | $0.00 Strike: $75.36 | $0.00 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · derivative · entry 7 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,020 Underlying: Common Stock · 41,509 shares Expires 2030-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F5 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
SaleCommon Stock | 25,324 | $126.37 | $3,200,277.45 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · nonDerivative · entry 4 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,326.757 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.2650 to $126.525, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
SaleCommon Stock | 124,676 | $125.74 | $15,677,146.74 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · nonDerivative · entry 3 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,650.757 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.2700 to $126.2600, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:01 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
Exercise / conversionCommon Stock | 108,491 | $73.73 | $7,999,041.43 |
DisclosureSEC source: 0001127602-24-005191 · form4.xml · nonDerivative · entry 2 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,326.757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.